Transaction #30619 · Form 4 · 0001193125-26-414218
Cogent Biosciences, Inc. · Stock award · Stock Option (Right to Buy)
Cogent Biosciences, Inc. · Transacted October 1, 2026 · Filed October 5, 2026
What does this filing report?
An SEC Form 4 filing for Cogent Biosciences, Inc. records a stock award involving Stock Option (Right to Buy) on October 1, 2026. The reported quantity was 759. The filing date is October 5, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Cogent Biosciences, Inc.
- Company CIK
- 0001622229
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 759
- Reported price
- 0 · See footnotes
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 759
- Ownership description
- Not reported
- SEC acceptance time
- Oct 5, 2026, 4:30 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Ferrante Karen Jean ↗
Director
CIK 0001598502
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 759
- Conversion / exercise price
- 31.59
- Exercise date
- October 1, 2026
- Expiration date
- October 1, 2036
Filing footnotes & remarks
- F1
- The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.